NightHawk Biosciences Inc (NHWK)

[dia76ca]

Heat Biologics Announces Pricing For Rights Offering To Stockholders
Get notified next time HTBX.US makes a similar move!

DURHAM, NC ? October 16, 2017

? Heat Biologics, Inc. (?Heat?) (Nasdaq: HTBX), a biopharmaceutical company developing drugs designed to activate a patient?s immune system against cancer, has announced the subscription price of $0.62 per share, for an intended rights offering to Heat?s existing security holders.

Under the proposed rights offering, Heat will distribute non-transferable subscription rights to purchase shares of common stock to its eligible stockholders and participating warrant holders as of the October 13, 2017 record date.

Holders who exercise their subscription rights in full will be entitled to subscribe for additional shares that are not purchased by other shareholders.

The registration statement relating to the rights offering has been filed with the SEC, but has not yet become effective.

Expected Subscription Period:

Beginning date:

Friday, Oct. 20, 2017

Ending date:   

Wednesday, Nov. 8, 2017 by 5 p.m. ET

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities; nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient?s immune system against cancer using of CD8+ ?Killer? T-cells. Our T-Cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot" and be administered in combination with checkpoint inhibitor therapies and other immuno-modulators to increase their effectiveness. We are currently enrolling patients in our Phase 2 clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb?s nivolumab (Opdivo®). We also have numerous pre-clinical programs at various stages of development.

For more information, please visit www.heatbio.com.